AIxCrypto 

$0.9902
41
+$0.07+7.61% 08:00 Today

Statistics

Day High
1.03
Day Low
1.01
52W High
8.81
52W Low
0.896
Volume
4,051
Avg. Volume
-
Mkt Cap
20.04M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18AugExpected
Q1 2024
Q2 2025
Q3 2025
Q1 2026
Next
-26
-17.6
-9.19
-0.79
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-19.53MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AIXC. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is a biopharmaceutical company that competes in the development of therapeutics in areas similar to Qualigen, such as viral diseases, making it a direct competitor.
AMGEN
AMGN
Mkt Cap196.12B
Amgen is a biotech firm focusing on human therapeutics, including treatments for illnesses that Qualigen also targets, positioning it as a competitor.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb operates in the biopharmaceutical field, developing prescription drugs that overlap with Qualigen's therapeutic areas.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is a global pharmaceutical corporation with a broad product portfolio that includes treatments in areas competing with Qualigen's focus.
Merck
MRK
Mkt Cap305.12B
Merck & Co. is known for its innovative medicines and vaccines, some of which directly compete with Qualigen's product pipeline.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie is a research-based biopharmaceutical company with a strong emphasis on developing innovative therapies, including those in competition with Qualigen.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of medicines for serious conditions, competing with Qualigen's therapeutic areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals is focused on creating new possibilities in medicine to cure diseases and improve people's lives, including areas where Qualigen operates.
Novartis
NVS
Mkt Cap293.94B
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide, including in sectors where Qualigen is active.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a wide range of medical therapies that compete with Qualigen's developments.

About

AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
Show more...
CEO
Mr. Michael S. Poirier
Employees
4
Country
United States
ISIN
US74754R3012

Listings

0 Comments

Share your thoughts

FAQ

What is AIxCrypto stock price today?
The current price of AIXC is $0.99 USD — it has increased by +7.61% in the past 24 hours. Watch AIxCrypto stock price performance more closely on the chart.
What is AIxCrypto stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange AIxCrypto stocks are traded under the ticker AIXC.
What is AIxCrypto market cap?
Today AIxCrypto has the market capitalization of 20.04M
When is the next AIxCrypto earnings date?
AIxCrypto is going to release the next earnings report on August 18, 2026.
What were AIxCrypto earnings last quarter?
AIXC earnings for the last quarter are -0.79 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is AIxCrypto revenue for the last year?
AIxCrypto revenue for the last year amounts to 0 USD.
What is AIxCrypto net income for the last year?
AIXC net income for the last year is -19.53M USD.
How many employees does AIxCrypto have?
As of July 15, 2026, the company has 4 employees.
In which sector is AIxCrypto located?
AIxCrypto operates in the Health & Wellness sector.
When did AIxCrypto complete a stock split?
AIxCrypto has not had any recent stock splits.
Where is AIxCrypto headquartered?
AIxCrypto is headquartered in Carlsbad, United States.